



Features of Genetic Polymorphism in Population with Diabetic Nephropathia: Literature Review

O. O. Jabborov^{1*}

¹*Faculty and Hospital Therapy N.2, Tashkent Medical Academy, Tashkent, Uzbekistan.*

Author's contributions

This work was carried out by single author. Author OOJ designed the study, performed the statistical analysis, wrote the protocol, wrote the first draft of the manuscript, managed the analyses of the study and managed the literature searches. Author read and approved the final manuscript.

Article Information

DOI:10.9734/JAMMR/2019/v29i930123

Editor(s):

(1) Dr. Kate S. Collison, Department of Cell Biology, King Faisal Specialist Hospital & Research Centre, Saudi Arabia.

Reviewers:

(1) Dr. Brijesh Mukherjee, Hi Tech Medical College & Hospital Rourkela, India.

(2) Mohd Jokha Yahya, Hospital Kuala Lumpur, Malaysia.

(3) Dr. J. Y. Peter, University of Abuja, Nigeria.

Complete Peer review History: <http://www.sdiarticle3.com/review-history/46907>

Received 15 November 2018

Accepted 23 January 2019

Published 08 May 2019

Review Article

ABSTRACT

The increasing prevalence of diabetes mellitus has led to a growing number of chronic complications including diabetic nephropathy (DN). In high prevalence of diabetes mellitus, DN is associated with high morbidity and mortality primarily due to cardiovascular diseases. Genetic factors play a significant role in the pathogenesis of DN and genetically susceptible individuals that can develop after being exposed to environmental parameters. DN is assumed to be a complex, polygenic disease. Genetic predisposition to diabetes is familial, and often with concomitant obesity. A number of detected polymorphisms in genes is a predisposing risk factor for the development of type 2 diabetes. Two main categories have been used to identify the genes associated with DN: (1) analysis of candidate genes, and (2) more recently genome-wide scan. A significant effort has been made to identify these main genes, whereas results are still inconsistent with different genes associated to a small effect in specific populations. A variety of genetic markers characteristic of different population groups confirms the special significance of the ethnic component for identifying hereditary risks, which determines the relevance and need for a detailed, comprehensive study of the genetic basis of type 2 diabetes.

*Corresponding author: E-mail: science.publication@mail.ru;

Keywords: *Diabetes mellitus; nephropathy; genetics; genetic predisposition; population; polymorphism.*

1. INTRODUCTION

Type 2 diabetes mellitus (DM2) is the most common endocrine disease, which is one of the most acute medical and social problems, as it leads to early disability and increased mortality among the population due to the development of various complications [1,2,3,4]. Currently, more than 285 million people in the world suffer from diabetes, in 90% of cases it is type 2 diabetes. There are more than 3 million people with diabetes in Russia, 2.8 million of them with type 2 diabetes. According to WHO forecasts, by 2025 the number of patients with diabetes in the world will increase to 435 million people [5-18, 19]. According to the frequency of disability and mortality, diabetes mellitus is on the 3rd place after cardiovascular diseases and oncologic pathology. Type 2 diabetes is considered a “non-infectious epidemic” [6].

With an increase in the life expectancy of patients with diabetes mellitus (DM), diabetic nephropathy (DN) is becoming an increasingly urgent problem in a series of late complications of diabetes, causing early disability and mortality. A complex issue of diabetology is kidney damage in patients with type 2 diabetes. It has been established that in patients with newly diagnosed type 2 diabetes, microalbuminuria (MAU) is detected in 15-40% of cases, proteinuria - in 7-10%, uremia - in 1%, which reflects the difficulties of timely diagnosis of type 2 diabetes [20]. Other forms of chronic kidney disease (CKD) can progress under the mask of DN in type 2 diabetes: renal artery stenosis, urinary tract infection, interstitial nephritis, contrast-induced nephropathy, tubulo-interstitial fibrosis and others [5].

As is known, the development of DN is the result of exposure to metabolic and hemodynamic factors. With the same glycemic control and the duration of the disease, DN can have different periods of occurrence and rate of progression in different patients, which made it possible to suggest a significant modulating effect of genetic factors [7,13,15].

2. ETIOLOGY AND RISK FACTORS

Diabetic nephropathy (DN) is one of the most formidable vascular complications, the main cause of the development of terminal renal

failure. Mortality from uremia in type 1 diabetes reaches 30-50% [2,9]. Currently, patients with diabetes are in the first place among patients who need treatment with chronic hemodialysis [8,10,11].

2.1 Risk Factors

The onset and progression of diabetic nephropathy cannot always be explained by traditional risk factors such as hyperglycemia, arterial hypertension or dyslipidemia. It is known that even with ideal compensation characteristic diabetic patients form characteristic lesions in the kidneys [21,22]. On the other hand, there are cases when patients with long-term decompensation of diabetes can experience only minor changes in the kidneys and, therefore, we can assume the existence of other equally important factors in the development of vascular complications, in particular genetic factors [14,23].

Currently, thanks to the development of molecular research methods, about 200 tests have been developed that allow the identification of hereditary predispositions to various diseases [12].

2.2 Genetic Mutation and Its Role in DM

The development of molecular genetic methods in modern biology makes it possible to reveal in detail the pathological-biochemical causes of the emergence of diseases (congenital, acquired), to use them in diagnostics and to promote new methods of correction in medical practice. The “genetic markers” of diabetes mellitus have shown that a number of diseases can be inherited, and in some of the population there are prerequisites for the occurrence of a disease [16,24].

Genetic polymorphism actually occurs as a result of replacing nucleotides with another in different parts of the human genome: introns, exons, and other DNA segments and can be caused by deletion, duplication, triplication, and translocation. This determines a huge number of gene differences [25,26,27].

Modern achievements of human genetics indicate the importance of genetic factors in determining the level of health of the population.

It is shown that a number of diseases can be inherited, and a part of the population has prerequisites for the occurrence of a particular disease. The genes and their protein products that are responsible for the development of such diseases were discovered. In laboratory practice, they are sometimes called "genetic markers" [18,21]. The study of such markers makes it possible to identify groups of various risk of developing diseases, and in particular, diabetes. Such an approach can simplify the early diagnosis of the disease, before the onset of the main clinical features [28].

More than 30 thousand genes have already been identified on the physical map of the human genome, about 10–11 thousand have been studied functionally [17,29,30]. There is a growing list of hereditary diseases for which molecular genetic diagnostic methods can be used [31,32]. This enables the development of methods for the prevention of these diseases [2].

By its nature, T2DM is a genetically determined disease with a polygenic type of inheritance. Today, due to the active introduction of the technological advances of modern medical science into clinical practice, in particular, molecular genetic analysis methods, it becomes possible to develop approaches to the prevention and preclinical diagnosis of diabetes mellitus based on an understanding of the molecular basis of its etiology and pathogenesis [19,33].

Genetic predisposition to diabetes is familial, and often with concomitant obesity. A number of detected polymorphisms in genes is a predisposing risk factor for the development of type 2 diabetes. The products of these genes (proteins) are regulators of glucose metabolism. The structure of proteins encoded in the genes is mediated by those responsible for glucose homeostasis. Some polymorphisms in these genes can lead to disruption of the normal glucose metabolism. For example, polymorphism in the ADAMTS9 gene leads to a decrease in the sensitivity of peripheral tissues to insulin, and increased expression of the TCF7L2 gene product leads to impaired glucose tolerance and is mediated to a decrease in insulin secretion [25,34]. The KCNJ11 and KCNQ1 genes contain information about the structure of proteins, mediated by participating in the regulation of insulin secretion. Disruption of the structure of these proteins (version 23K of the KCNJ11 gene) leads to a decrease in insulin release with an increase in glucose concentration [25].

2.3 Association between DM and HLA System

In assessing the possibility of the development of diabetes mellitus, a study of polymorphisms in the HLA (human leucocyte antigens) system has a definite role. Histocompatibility antigens (HLA-complex) - a human system consisting of a complex of genes and their products (proteins) that perform various biological functions, and first of all, provide genetic control of the immune response and the interaction between cells that implement this response [3,32].

The HLA genes of the second class include several dozen genes found in humans. HLA class II genes are located on B-lymphocytes, activated T-lymphocytes, monocytes. These cells produce proteins with certain properties that are necessary in regulating the recognition of foreign molecules [3,35].

In the study of the alleles of a number of HLA genes, especially with the frequency of occurrence of HLA genes of the second class, a relationship was found between their presence and an increased risk of the occurrence of such diseases as diabetes mellitus and autoimmune diseases. It was found that part of the allelic variants of the HLA class II genes are associated with an increased risk of developing type 1 diabetes mellitus [32,30].

Three genes, DQA1, DQB1 and DRB1, belong to the HLA class II genes that have the greatest clinical significance. DQA1, DQB1 and DRB1 are the so-called genes encoding class II tissue compatibility proteins – DQ and DR. Many people with diabetes are carriers of some HLA-DR3 and HLA-DR4 alleles. Since diabetes is a disease with a genetic predisposition, the study of combinations of these genes is a method of preliminary assessment of the possibility of the development of this disease [29,4,34].

Molecular biological methods for diagnosing diabetes mellitus are constantly being improved and introduced into clinical practice [24].

3. GENOTYPE OF DM AND POLYMORPHIC MARKERS

From a molecular genetic perspective, type 2 diabetes mellitus is not well understood. The overwhelming number of studies on the role of various candidate genes in the formation of T2DM and its complications have been carried

out abroad [36]. In the Russian Federation, only a few papers are devoted to molecular genetic aspects of type 2 DM [22]. For instance, according to S.V. Berstneva et al., genetic aspects of diabetic nephropathy in patients with type 2 DM was studied with its frequency, which was that alleles and genotypes distribution. They identified the association of polymorphic markers I/D of ACE gene, M234T of AGT gene, T-786C of NOS3 gene, and Lys198Asp of EDN 1 gene in patients with 2 type DM with a high risk of developing diabetic nephropathy. In results and their discussion, association between the D-allele carriage (genotype ID and DD) of the ACE gene and diabetic nephropathy in patients with type 2 diabetes has been identified [37,38].

The obtained results are consistent with the data of domestic and foreign authors, who showed that the D-allele carrier is an independent risk factor for DN in patients with diabetes type 1 and type 2 in different ethnic groups [6]. Significant association of the I/D ACE gene with the risk of end-stage renal failure in patients with type 2 diabetes in the Asian population were showed in a data from meta-analysis published in 2011 [1]. However, in the study which was conducted over Moscow population, there were no found an association of this polymorphic marker with the development of DN and CKD in patients with type 2 diabetes was obtained [7].

A comparative analysis of the frequency distribution of alleles and genotypes of the M235T polymorphism of the AGT gene carried out by the authors who did not reveal significant differences in patients with and without DN in the examined population [33]. As mentioned above, the literature data on this issue are rather contradictory and probably depend on the ethnic characteristics of the sample. According to some authors, synergism of the ACE and AGT genes: a joint analysis of the markers of the ACE gene and M235T of the AGT gene indicated a predominance of more severe kidney damage in individuals with the TT genotype with their U and DD genotypes. Based on this, it was concluded that the TT genotype has a modulating effect on the negative role of the D allele in the progression of renal pathology [23], but this is not confirmed in all publications. In our study, the association of the indicated genetic polymorphisms with DN in the groups of examined patients was also not detected.

In the Mexican population, it would be important to study the association of the ELMO1 and TJP1 genes with diabetic nephropathy (determinants of

filtration barrier homeostasis), given that they are polymorphic markers in this population, and these have already been established as risk markers for renal diseases [17,18]. At the level of carbohydrate metabolism regulators, the ATXN2 gene is also associated with diabetes and determines the filtration rate [29,21]. In this sense, MAGI1 gene is a prospective candidate. This gene is involved in glucose homeostasis and is part of the cytoskeleton podocyte. The c.12345C>T variant is polymorphic and is associated with an elevated fasting glucose level, which determines the progression of kidney damage, for these reasons it may be due to DN [19]. It would be worthwhile to pick up the DRB1*1502 allele from the MHC class II genes, which in Mexican has long been established that the population is associated with the terminal stage of renal failure and to analyze the connection with albuminuria [31]. Given the genetic diversity of the Mexican population and the complexity of type 2 diabetes, it is necessary to look for more candidate genes that explore the risk of developing diabetic nephropathy [28].

In the European population, the detectability of the TT, TC and CC variants of the promoter in position 786 of the NOS3 gene varies considerably: 29.9-40.6%; 41.3-52.3% and 13.5-17.8%, respectively [2].

A molecular genetic study of the polymorphic variants of four genes was carried out in the Azerbaijani population by Sardarly F.Z. et al., c-233+8274C>T g.4682G>A, and adiponectin gene ADIPOQ (g.93054571A>G) (rs4994).

It can be concluded that the patients with DM in Azerbaijani nationality showed a high incidence of the AG genotype (62.5%) leptin gene (relative risk (RR)=2.50 (1.09-5.72)), GG genotype (100%) of the gene TNF- α (RR=20.71 (1.08-396.39)), AA genotype (97.2%) of the adiponectin gene (RR=3.28 (0.52-20.51)), (RR=20.71 (1.08-396.39)) and the CC genotype (97.0%) of the polymorphic Pro12Ala marker of the PPAR γ 2 gene (RR=1.23 (0.23-6.47)). In patients with type 2 diabetes of the Azerbaijani population, single-nucleotide polymorphism rs1800629 of the FNO- α gene should be considered as a marker for the development of diabetic nephropathy [39].

Bondar I.A. et al. have studied the associations of the polymorphic markers rs7903146 of the TCF7L2 gene and rs1801282 of the PPAR γ Pro12Ala gene with type 2 diabetes mellitus (SD2) in the Novosibirsk region. The study

demonstrated that the carrier of the 12Pro allele of the polymorphic rs1801284 marker of the PPARG gene and the T allele of the polymorphic rs7903146 marker of the TCF7L2 gene is associated with the development of T2DM in the Novosibirsk Region. The combination of risk genotypes of the polymorphic markers rs1801282 of the PPARG gene and rs7903146 of the TCF7L2 gene in patients with type 2 diabetes in the Novosibirsk region reaches 74.4% [13].

Using genetic markers, you can identify groups of people with a risk of developing diabetes. This is an important step in the diagnosis of diabetes, because in combination with traditional methods (determination of glucose, glycated hemoglobin, hormones, detection of autoantibodies) leads to improved diagnosis of the disease before the manifestation of pronounced clinical symptoms of the disease and helps to develop human behavior and take preventive measures [40].

4. CONCLUSION

In recent years, genetic aspects of the development of type 2 diabetes, its complications and associated metabolic disorders in many populations have been actively studied. Currently in French (Sladek et al, 2007), Finnish and Swedish (Saxena et al. 2007), British (Zeggini et al. 2007), Icelandic (Steinthaorsdottir et al, 2007), Chinese (Tsai et al. 2010), Japanese (Yama ucli et al. 2010) and other populations, groups of polymorphic genetic markers associated with the development of type 2 diabetes were established.

However, in the Uzbek population, genetic markers of type 2 diabetes with DN were not studied. Despite the understanding of the significant role of hereditary factors in the formation of T2DM, the genetic component responsible for its development has not yet been fully established. Obviously, this is due to its complex nature, as a multifactorial disease, that is, with the need to study the role of a large number of polymorphic genetic markers and their interactions, as well as the relationship between hereditary predisposition and environmental factors. A variety of genetic markers characteristic of different population groups confirms the special significance of the ethnic component for identifying hereditary risks, which determines the relevance and need for a detailed, comprehensive study of the genetic basis of type 2 diabetes. Therefore, it was interesting for us to study the genetic

predispositions of DN in type 2 diabetes in the Uzbek nation.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Dedov II, Shestakova MV. Algorithms of specialized medical care for patients with diabetes. M. 2013;118.
2. Parkhomenko N, Kozhuhov SN, Lutaya M, Moybenko AA, Dosenko E. T-786C polymorphism of promoter endothelial NO synthase: A link with the effectiveness of thrombolytic therapy of patients with acute myocardial infarction. Ukr. Herald log. 2008;4(66):20-23.
3. Giusti B, Gori AM, Marcucci R, Sestini I, Saracini C, Sticchi E, et al. Role of C677T and A1298C MTHFR, A2756G MTR and -786 T/C eNOS gene polymorphisms in atrial fibrillation susceptibility, PLoS One. 2007;2:495.
4. Thameem F, Puppala S, Arar NH, Stern MP, Blangero J, Duggirala R, et al. Endothelial nitric oxide synthase (eNOS) gene polymorphisms and their association with type 2 diabetes-related traits in Mexican Americans, Diab. Vasc. Dis. Res. 2008;5:109-113.
5. Bondar IA, Shabelnikova O. Yu. Genetic bases of type 2 diabetes // Diabetes mellitus. 2013;4:11-16.
6. Berstneva SV, Dubinina II, Pronkina VV. Association of the polymorphic marker T-786C of the NOS3 gene with impaired endothelial function and increased stiffness of the arteries in patients with diabetes mellitus in combination with hypothyroidism/ Mater Pallrussia. Diabetic congress. Moscow. 2015;32.
7. Levit Sh, Filippov Yul, Gorelyshev AS. Type 2 diabetes mellitus: Time to change the concept // Diabetes mellitus. 2013;4: 91-102.
8. Zheleznyakova AV, Lebedeva NO, Vikulova OK, Nosikov VV, Shamkhalova M

- Sh, Shestakova MV. The risk of developing chronic kidney disease in patients with type 2 diabetes mellitus is determined by the polymorphism of the NOS3, APOB, KCNJ11, TCF7L2 genes. *Diabetes*. 2014; 3:23-30.
9. Potapov VA. Search for genetic markers that determine the predisposition to diabetes mellitus type 2: Author's thesis for Candidate biol. sciences. M. 2010;24.
 10. Pakhomya NS, Uryasev OM, Shakhanov AV. The role of polymorphisms of some genes in the implementation of arterial hypertension. *Zemsky Doctor*. 2014; 3-4(24):21-24.
 11. Savelieva SA, Kryachkova AA, Zheleznyakova AV, et al. The study of the polymorphic marker Pro12Ala of the gene of the γ form of receptors activated by proliferator peroxis in patients with type 2 diabetes with diabetic nephropathy // *Mater. VII Congress of the Scientific Society of Nephrologists of Russia*. M., 2010;C:110-111.
 12. *Diabetes. Acute and chronic complications*. Ed. I.I. Dedova, M.V. Shestakova. M: MIA, 2011;197.
 13. Hamnueva L. Yu, Andreeva LS, Shagun OV. Diabetes mellitus and its complications: Modern principles of diagnosis, treatment and prevention. Irkutsk: IGMU. 2011;138.
 14. Shestakova MV, Shamkhalova M. Sh, Yarek-Martynova I. Ya. Diabetes mellitus and chronic kidney disease: Achievements, unresolved problems and prospects for treatment // *Diabetes mellitus*. 2011;1:81-87.
 15. Shestakova MV. Diabetes mellitus and chronic kidney disease: modern diagnosis and treatment. *Bulletin of RAMS*. 2012;1: 45-49.
 16. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes// *N Engl J Med*. 2008;358(24):2560-72.
 17. Borg H, Arnqvist HJ, Bjork E, Bolinder J, Eriksson JW, Nystrom L, et al. Evaluation of the new ADA and WHO criteria for classification of diabetes mellitus in young adult people (15-34 yrs) in the Diabetes Incidence Study in Sweden (DISS), *Diabetologia*, 2003;46:173-181. Erratum in, *Diabetologia*. 2004;47:154.
 18. Coll-de-Tuero G, Mata-Cases M, Rodriguez-Poncelas A, et al. Chronic kidney disease in the type 2 diabetic patients: Prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area// *BMC Nephrology*. 2012;13:87-95.
 19. Diabetic patients, effect of ACE gene DD on the progression of diabetic nephropathy, *Am. J. Kidney. Dis*. 2003;41: 943-949.
 20. Balabolkin MI, Dedov II, Klebanova EM. Insulin resistance. Molecular genetic mechanisms of development, diagnosis and correction in type 2 diabetes. M. 2007;36.
 21. Dellamea BS, Pinto LC, Leitao CB, Santos KG, Canani LH. Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: A systematic review and meta-analysis. *BMC Med. Genet*. 2014;15(9):2-13.
 22. Nannipieri M, Penno G, Pucci L, Colhoun H, Motti C, Bertacca A, et al. Pronatriodilatin gene polymorphisms, microvascular permeability, and diabetic nephropathy in type 1 diabetes mellitus, *J. Am. Soc. Nephrol*. 1999;10:1530- 1541.
 23. Schmidt S, Ritz E. Genetic determinants of diabetic renal disease and their impact on therapeutic interventions, *Kidney Int. Suppl*. 1997;63:27-31.
 24. Nagase S, Suzuki H, Wang Y, Kikuchi S, Hirayama A, Ueda A, et al. Association of eNOS gene polymorphisms with end stage renal diseases, *Mol. Cell. Biochem*. 2003;244:113-118.
 25. Freedman BI, Bowden DW. The role of genetic factors in the development of end-stage renal disease, *Curr. Opin. Nephrol. Hypertens*. 1995;4:230-234.
 26. Nelson RG, Tuttle KR, Bilous RW, et al. National kidney foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update// *Am J Kidney Dis*. 2012; 60(5):850-86.
 27. Noiri E, Satoh H, Taguchi J, Brodsky SV, Nakao A, Ogawa Y, et al. Association of eNOS Glu298Asp polymorphism with end-stage renal disease, *Hypertension*. 2002; 40:535-540.
 28. Yu ZY, Chen LS, Zhang LC, Zhou TB. Meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy. *Nephrology (Carlton)*. 2012;17(5):480-487.
 29. Chen Y, Huang H, Zhou J, Doumatey A, Lashley K, Chen G, et al. Polymorphism of

- the endothelial nitric oxide synthase gene is associated with diabetic retinopathy in a cohort of West Africans, *Mol. Vis.* 2007;13: 2142-2147.
30. Ng DP, Tai BC, Koh D, Tan KW, Chia KS. Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: A meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. *Diabetologia.* 2005;48(5):1008-1016.
 31. Freitas-Silva M, Pereira D, Coelho C, Bicho M, Lopes C, Medeiros R. Angiotensin I-converting enzyme gene insertion/deletion polymorphism and endometrial human cancer in normotensive and hypertensive women, *Cancer. Genet. Cytogenet.* 2004;155:42-46.
 32. Lukacs K, Hosszufalusi N, Dinya E, et al. The type 2 diabetes-associated variant in TCF7L2 is associated with latent autoimmune diabetes in adult Europeans and the gene effect is modified by obesity: a meta-analysis and an individual study// *Diabetologia.* 2012;55(3):689-93.
 33. Miyata T. Novel mechanisms and therapeutic options in diabetic nephropathy, *Pol. Arch. Med. Wewn.* 2009;119: 261-264.
 34. Thameem F, Puppala S, Arar NH, Stern MP, Blangero J, Duggirala R, et al. Endothelial nitric oxide synthase (eNOS) gene polymorphisms and their association with type 2 diabetes-related traits in Mexican Americans, *Diab. Vasc. Dis. Res.* 2008;5:109-113.
 35. Maeda Y, Shiigai T. Diet therapy in diabetic nephropathy, *Contrib. Nephrol.* 2007;155:50-58.
 36. Marre M, Jeunemaitre X, Gallois Y, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: (GENEDIAB) Study Group. *J. Clin. Invest.* 1997;99: 1585-1595.
 37. Li H, Louey JWC, Choy KW, Liu DTL, Chan WM. EDN1 Lys198Asn is associated with diabetic retinopathy in type 2 diabetes. *Molecular vision.* 2008;14:1698-1704.
 38. Tarnow L, Gluud C, Parving HH. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene, *Nephrol. Dial. Transplant.* 1998;13:1125-1130.
 39. Hodgkinson AD, Millward BA, Demaine AG. Polymorphisms of the glucose transporter (GLUT1) gene are associated with diabetic nephropathy, *Kidney Int.* 2001;59:985-989.
 40. Shin Shin Y, Baek SH, Chang KY, Park CW, Yang CW, Jin DC, et al. Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy, *Diabetes Res. Clin. Pract.* 2004;65:257-265.

© 2019 Jabborov; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<http://www.sdiarticle3.com/review-history/46907>